Price (delayed)
$0.8907
Market cap
$39.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
-$33.98M
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its
There are no recent dividends present for HOWL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.